FindTrial
Sign In

Biomarker exploration in patients undergoing boron neutron capture therapy (BNCT).

Biomarker exploration in patients undergoing boron neutron capture therapy (BNCT). - Biomarker exploration in patients undergoing boron neutron capture therapy (BNCT).

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000050486
Enrollment
50
Registered
2023-03-20
Start date
2023-02-07
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who received BNCT at National Cancer Center Hospital and gave consent to participate in this study.

Exclusion criteria

Exclusion criteria: Patients for whom the necessary samples for analysis could not be obtained.

Design outcomes

Primary

MeasureTime frame
metabolome analysis, proteome analysis, comprehensive analysis of tumor gene aberrations and gene expression aberrations, comprehensive gene expression analysis of tumor-infiltrating immune cells, protein expression analysis of tumor-infiltrating immune cells, LAT-1 expression analysis—

Secondary

MeasureTime frame
Correlations between clinical information and pharmacokinetics and the primary endpoints will be examined.—

Countries

Japan

Contacts

Public ContactTairo Kashihara

National Cancer Center Hospital Department of Radiation Oncology/Division of Boron Neutron Capture Therapy Medical Research

tkashiha@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026